Examples & testimonials

Maximizing the VALUE we can deliver to patients through partnerships

Astellas team members and a new Astellas partner sharing ideas around a table, discussing future plans for their new partnership.

Proven successes and an ambitious future 

Strong and meaningful partnerships have played an important role in establishing our proven track record of successful innovation, our broad pipeline and our expertise in novel modalities.

 

We have discovered, developed and commercialized paradigm-changing treatments for patients in oncology, ophthalmology, urology, immunology and women’s health. We can also scale up global capabilities quickly, for example, we built a leading oncology franchise in just over a decade.

 

Our early pipeline is our hub for transformational therapies in emerging fields. We start with a deep understanding of disease biology to identify the most suitable, cutting-edge modalities and treatment opportunities, such as cell and gene therapy, that could be life-changing for patients across many different diseases.

 

We are already creating expandable platforms and continue to seek deals and investments in capabilities that will propel us and our partners towards delivering value.

Here is a sampling of some of our world-class partnerships

For Astellas, each new partnership, collaboration or acquisition is an opportunity to enhance our shared potential and deliver more for patients, faster. We value the experience, science and expertise of our partners and the following testimonials capture our approach to collaboration and prioritization of a shared, inclusive culture where innovation thrives.  

Portfolio
Track Record

Partnerships, collaborations and acquisitions

Collaboration started on November 23, 2021

Astellas and Dyno Therapeutics entered a long-term research collaboration to develop next generation adeno-associated virus (AAV) gene therapy vectors for skeletal and cardiac muscle. These are intended to provide meaningful value for patients with genetic diseases who currently have few or no effective treatment options.

“Astellas is a world leader in gene therapies, with several AAV pipeline assets and deep expertise in AAV optimization. Astellas and Dyno also share the ambition of advancing the field of gene therapy more broadly, in particular by using next-generation AAV technology to deliver transformative gene therapies to patients. The strengths of our respective teams and our long term commitment to innovation in gene therapy convinced me this would be a winning combination for bringing outstanding new therapies to patients.”

Eric D. Kelsic, Ph.D.

Dyno’s CEO and Co-founder

DYNO Therapeutics, a successful Astellas partnership

*Quote from the press release:

Collaboration started on June 14, 2023

Astellas and Cullgen entered a research collaboration and exclusive option agreement, working towards the discovery of multiple innovative protein degraders with increased efficacy, reduced toxicity, enhanced tissue selectivity and the ability to overcome drug resistance. The partnership won the Licensing Executives Society ‘2022-2023 Deal of Distinction’ award, reflecting Astellas’ and Cullgen’s close collaboration to align on shared goals and ensure a smooth kick-off once the deal was signed.

“We are excited to enter into this strategic collaboration with Astellas using our novel E3 ligands which we discovered in-house. We are looking forward to working with Astellas to advance more targeted protein degraders into clinical development." 

Ying Luo, Ph.D.

President and CEO at Cullgen

Cullgen, a successful Astellas partnership

*Quote from the press release:

Collaboration started on March 23, 2020

Astellas entered a strategic collaboration with CytomX Therapeutics focused on the discovery, research, development and commercialization of novel T-cell engagers for bispecific therapies as cancer treatments.

“We are excited about the use of our technology to assist Astellas in unlocking the potential of T-cell engagers (TCE) in the treatment of solid tumors, building on the growing proof of concept we have established for our platform. This collaboration with Astellas leverages CytomX’s deep expertise in targeting multiple antibody modalities to the tumor microenvironment. We have achieved two clinical candidate nomination since the start of this collaboration. Such continued momentum toward the potential future IND for the first PROBODY® TCE clinical candidate highlights the benefits of our strategy to create value through both wholly-owned and partnered programs.”

Sean A. McCarthy, D.Phil.

Chief Executive Officer and Chairman

CYTOMX Therapeutics, a successful Astellas partnership

*Quote from the press release:

Voice from a company that joined Astellas

Acquired on July 11, 2023

Astellas acquired Iveric Bio, in pursuit of the discovery and development of novel treatments in the field of ophthalmology. Discussions with Iveric Bio initially explored a licensing agreement, but with openness, creativity and cooperation, both parties agreed that an acquisition would best serve our long-term strategic view.

“The opportunity to create a world-class entity with the ophthalmology expertise and capabilities of Iveric Bio and the global reach and resources of Astellas is unique and has the potential to benefit patients worldwide suffering from blinding retinal diseases, including geographic atrophy.”

Pravin U. Dugel, MD,

President of Iveric Bio.

Iveric Bio, a successful Astellas partnership

Press Release:

Astellas Enters into Definitive Agreement to Acquire Iveric Bio arrow_right_alt

If you share our passion for innovation and delivering meaningful value to patients, we would love to hear from you. You can reach us here.

Areas of interest